4.3 Article

Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components

期刊

VIRCHOWS ARCHIV
卷 478, 期 4, 页码 669-678

出版社

SPRINGER
DOI: 10.1007/s00428-020-02954-x

关键词

Tumor-infiltrating lymphocyte; Program death-ligand 1; Metaplastic breast carcinoma

资金

  1. National Science Council [NSC 108-2320-B-002-061]

向作者/读者索取更多资源

The study revealed differences in immune microenvironments between different metaplastic components in metaplastic breast carcinoma, with distinct expression patterns of sTIL and PD-L1 in the various components compared to carcinoma of no special type (NST). These findings suggest potential implications for immunopathology, diagnosis, and therapy in MBC.
Both stromal tumor-infiltrating lymphocytes (sTILs) and programmed death-ligand 1 (PD-L1) affect responses to immunotherapy; however, the extent of sTIL and PD-L1 expression within various metaplastic components in metaplastic breast carcinoma (MBC), which are critical for the characterization of immune microenvironments, remains unreported. We profiled sTIL infiltration and PD-L1 expression in different metaplastic components of specimens from 82 MBC patients. The overall positivity for high or intermediate (H/I) sTIL, immune cell-PD-L1 (IcPD-L1), and tumor cell-PD-L1 (TcPD-L1) was 34.1%, 47.6%, and 17.1%, respectively, but differences specific to MBC subtypes and each metaplastic component existed. Squamous cell carcinoma exhibited the highest positivity rates of sTIL(H/I) (50.0%) and IcPD-L1 (66.7%), while matrix-producing carcinoma had the lowest respective rates (14.3% and 28.6%). The positivity rates of sTIL(H/I) and IcPD-L1 were the highest in squamous component (Sq) and the lowest in chondroid component (Ch). All cases that had discordant sTIL categories between carcinoma of no special type (NST) and metaplastic components showed sTIL(H/I) positivity higher in Sq, but lower in spindled component (Sp) and Ch. While there was no pattern of higher IcPD-L1-positivity in Sp, six of the seven cases that were TcPD-L1-discordant between NST and Sp were TcPD-L1-positive in Sp, suggesting a trend for higher TcPD-L1 in Sp. The diagnostic predictability of total tumor IcPD-L1 positivity based on IcPD-L1 positivity in Sq and Ch was 95.2% and 33.3%, respectively. Multivariate analysis showed that sTIL(H/I) positivity, but not PD-L1 positivity, correlated with better survival. Our data implicate distinct immune microenvironments in different metaplastic components in MBC, which may have immunopathologic, diagnostic, and therapeutic significance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Analytical

Development of an efficient mAb quantification assay by LC-MS/MS using rapid on-bead digestion

Huai-Hsuan Chiu, Yun-Jung Tsai, Chiao Lo, Ching-Hung Lin, I-Lin Tsai, Ching-Hua Kuo

Summary: This study developed an efficient LC-MS/MS method using an on-bead trypsin digestion procedure to quantify mAb therapeutics. The method showed better sensitivity and reproducibility, making it suitable for real-world analysis of a large number of clinical samples and contributing to personalized mAb treatment.

ANALYTICA CHIMICA ACTA (2022)

Article Oncology

Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients

Po-Han Lin, Shin-Cheh Chen, Ling-Ming Tseng, King-Jen Chang, Ai-Chu Huang, Kuo-Chih Cheng, Karen Yang, Hui-Chen Wu, Tsu-Yi Chao, Yuan-Ching Chang, Peng-Chan Lin, Wen-Hung Kuo, Wen-Lin Kuo, Ching-Hung Lin, Huo-Mu Chen, Dah-Cherng Yeh, Liang-Chih Liu, Chun-Yu Liu, Ming-Yang Wang, Chiao Lo, Yen-Shen Lu, Chiun-Sheng Huang

Summary: The study found that Asian breast cancer patients with BRCA mutations had a higher risk of developing contralateral breast cancer, especially for BRCA1 mutation carriers with triple-negative breast cancer as their first breast cancer. However, there were no significant differences in relapse-free survival and overall survival between mutation carriers and control patients.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Article Oncology

Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan

Tom Wei-Wu Chen, Ruru Chun-Ju Chiang, Alex Le Cesne, Yu-Chun Hsieh, Antoine Italiano, Ya-Wen Yang, Nicolas Penel, Wen-Chung Lee, Emmanuelle Bompas, Thibaud Valentin, Philippe Anract, Nelly Firmin, Florence Duffaud, Ann-Lii Cheng, Francoise Ducimetiere, K. Arnold Chan, Jean-Yves Blay

Summary: The study found significant differences in the incidence and clinical characteristics of soft tissue sarcoma (STS) among different geographic and ethnic populations, suggesting that geographic and ethnic factors may play a crucial role in the pathogenesis of STS.

CANCER (2022)

Article Oncology

A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Tom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, Jen-Chieh Lee, Koping Chang, Chih-Wei Yu, San-Chi Chen, Jhe-Cyuan Guo, Mei-Lu Chen, Meng-Chi Hsu, Ting-Fang Kung, Ann-Lii Cheng, Chueh-Chuan Yen

Summary: The LEADER study investigated the safety and efficacy of lenvatinib in combination with eribulin for the treatment of advanced leiomyosarcoma and liposarcoma. The study showed that this combination therapy has a manageable safety profile and demonstrates promising efficacy.

CLINICAL CANCER RESEARCH (2022)

Article Oncology

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices

Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu

Summary: Pseudocirrhosis is a common finding in liver metastasis, and its presence can lead to a shorter overall survival in patients with metastatic breast cancer. The presence of esophageal or gastric varices is associated with poorer outcomes in these patients.

ONCOLOGIST (2022)

Article Oncology

Estrogen-DNA Adducts and Breast Cancer Risk in Premenopausal Asian Women

Ching-Hung Lin, Muhammad Zahid, Wen-Hung Kuo, Ming-Yang Wang, Fu-Chang Hu, I-Chun Chen, Cheryl L. Beseler, Bodhisattwa Mondal, Yen -Shen Lu, Eleanor G. Rogan, Ann-Lii Cheng

Summary: The incidence of breast cancer among premenopausal women in East Asia has been increasing rapidly. This study found that the ratio of estrogen-DNA adducts in plasma was significantly higher in the case group compared to the control group, and it was a significant predictor of breast cancer risk in premenopausal women.

CANCER PREVENTION RESEARCH (2023)

Article Multidisciplinary Sciences

Deep-learning based breast cancer detection for cross-staining histopathology images

Pei-Wen Huang, Hsu Ouyang, Bang-Yi Hsu, Yu-Ruei Chang, Yu-Chieh Lin, Yung-An Chen, Yu-Han Hsieh, Chien-Chung Fu, Chien-Feng Li, Ching-Hung Lin, Yen-Yin Lin, Margaret Dah-Tsyr Chang, Tun-Wen Pai

HELIYON (2023)

Review Public, Environmental & Occupational Health

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent

Summary: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, has shown improved outcomes for patients with HER2-positive and HER2-low metastatic breast cancer. Monitoring and managing T-DXd-related adverse events (AEs) is a growing need, and experts from the Asia-Pacific region provided recommendations based on clinical trial evidence and regional healthcare considerations. Proactive monitoring and management are crucial for maximizing the benefits of T-DXd.

DRUG SAFETY (2023)

Review Oncology

Disparity in survival benefits of pembrolizumab between Asian and non-Asian patients with advanced cancers: A systematic review and meta-regression analysis

Shang-Hsuan Peng, Ching-Hung Lin, I-Chun Chen, Ying-Chun Shen, Dwan-Ying Chang, Tom Wei-Wu Chen, Shu-Min Huang, Fu-Chang Hu, Yen-Shen Lu

Summary: This systematic review found that Asian patients with advanced cancers may derive superior overall survival benefits from pembrolizumab compared to non-Asian patients. However, no significant difference was found in progression-free survival. The study also identified the open-label design as a key covariate that favored non-Asian participants. These findings provide important insights into clinical research design.

CANCER MEDICINE (2023)

Article Oncology

Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study

Ming-Shen Dai, Ta-Chung Chao, Chang-Fang Chiu, Yen-Shen Lu, Her-Shyong Shiah, Christopher G. C. A. Jackson, Noelyn Hung, Jianguo Zhi, David L. L. Cutler, Rudolf Kwan, Douglas Kramer, Wing-Kai Chan, Albert Qin, Kuan-Chiao Tseng, Cheung Tak Hung, Tsu-Yi Chao

Summary: This study investigated the pharmacokinetics, overall response rate, and safety of weekly oral paclitaxel with encequidar in patients with advanced breast cancer. The results showed that the combination therapy produced consistent therapeutic plasma paclitaxel exposure and had a high clinical benefit rate, with a low rate of neurotoxicity.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2023)

暂无数据